Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese firm simultaneously announces that it has inked a monoclonal antibody discovery deal with Xoma.
You may also be interested in...
Takeda Expands Antibody Collaboration With Xoma
Agreement now could earn California company $230 million before royalties for identifying therapeutic antibodies that target cancer.
Takeda Expands Antibody Collaboration With Xoma
Agreement now could earn California company $230 million before royalties for identifying therapeutic antibodies that target cancer.
Takeda Expands Antibody Collaboration With Xoma
Takeda and Xoma expanded their discovery and development agreement, increasing the number of therapeutic antibody programs and raising Xoma's potential earnings to $230 million, not including royalties, the companies announced Feb. 28